昭衍新药（603127）(06127)发布公告，预计2025年实现营业收入约人民币15.73亿元到人民币17.38亿 元，与上年同期的数据相比，将减少约人民币2.8亿元到人民币4.46亿元，同比减少约13.9%到22.1%。 预计2025年实现归属于公司股东的净利润约人民币2.33亿元到人民币3.49亿元，与上年同期的数据相 比，将增加约人民币1.59亿元到人民币2.75亿元，同比增加约214.0%到371.0%。 本报告期内，生物资产市场价格上涨叠加自身自然生长增值，双重因素驱动其公允价值正向变动，为公 司业绩做出积极贡献。本报告期内，公司实验室继续保持良好稳定的运营状态，但受前期行业竞争剧烈 的滞后影响，本报告期履约合同的收入和毛利率同比降低，实验室服务业务利润贡献下降。 预计2025年实现归属于公司股东的扣除非经常性损益的净利润约人民币2.46亿元到人民币3.7亿元，与上 年同期的数据相比，将增加约人民币2.23亿元到人民币3.46亿元，同比增加约945.2%到1,467.7%。其 中：生物资产公允价值变动贡献的净利润约人民币4.52亿元到人民币5亿元。实验室服务及其他业务净 利润约人民币-2.06亿元 ...

Group 1 - The company expects to achieve operating revenue of approximately RMB 1.573 billion to RMB 1.738 billion in 2025, representing a decrease of about RMB 280 million to RMB 446 million compared to the previous year, which is a year-on-year decline of approximately 13.9% to 22.1% [1] - The projected net profit attributable to shareholders for 2025 is expected to be around RMB 233 million to RMB 349 million, an increase of approximately RMB 159 million to RMB 275 million compared to the previous year, reflecting a year-on-year increase of about 214.0% to 371.0% [1] - The expected net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be approximately RMB 246 million to RMB 370 million, which is an increase of about RMB 223 million to RMB 346 million year-on-year, indicating a significant increase of approximately 945.2% to 1,467.7% [1] Group 2 - The increase in the fair value of biological assets is driven by rising market prices and natural growth, contributing positively to the company's performance [2] - The laboratory services segment continues to operate steadily; however, revenue and gross margin from performance contracts have decreased year-on-year due to prior intense industry competition, leading to a decline in profit contribution from laboratory services [2]

预计2025年实现归属于公司股东的净利润约人民币2.33亿元到人民币3.49亿元，与上年同期的数据相 比，将增加约人民币15,853.52万元到人民币27,484.06万元，同比增加约214.0%到371.0%。 预计2025年实现归属于公司股东的扣除非经常性损益的净利润约人民币24,638.00万元到人民币36,956.99 万元，与上年同期的数据相比，将增加约人民币22,280.66万元到人民币34,599.65万元，同比增加约 945.2%到1,467.7%。其中：3.1生物资产公允价值变动贡献的净利润约人民币45,191.16万元到人民币 49,948.12万元。3.2实验室服务及其他业务净利润约人民币-20,553.16万元到人民币-12,991.13万元。 格隆汇1月20日丨昭衍新药(06127.HK)公告，按照集团截至2025年12月31日止年度(「报告期」)的未经 审核管理账目之初步评估以及董事会现时可得的资料，经财务部门初步测算如下：预计2025年实现营业 收入约人民币15.73亿元到人民币17.38亿元，与上年同期的数据相比，将减少约人民币28,019.80万元到 人民币44,573.47 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 盈利警告 2025年年度業績變動公告 本公告是由北京昭衍新藥研究中心股份有限公司（「本公司」，連 同 其 附 屬 公 司， 統稱為「本集團」）根據香港法例第571章《證 券 及 期 貨 條 例》第XIVA部及香港聯合 交易所有限公司證券上市規則（「上市規則」）第13.09條 而 作 出。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 一、本期業績預告情況 （一）業績預告期間 2025年1月1日 至2025年12月31日。 （二）業績預告情況 本公司董事會（「董事會」）謹 此 知 會 本 公 司 股 東 及 潛 在 投 資 者，按 照 本 集團截至2025年12月31日止年度（「報 ...

Group 1 - The core viewpoint of the news is that Zhaoyan New Drug (昭衍新药) is expected to achieve a significant increase in net profit for 2025, despite a decline in revenue, primarily driven by the fair value changes of biological assets, particularly experimental monkeys [1][2]. - The company forecasts a net profit attributable to shareholders of approximately 233 million to 349 million yuan for 2025, representing a year-on-year increase of about 214.0% to 371.0% [1]. - Zhaoyan New Drug anticipates revenue between 1.573 billion and 1.738 billion yuan for 2025, which reflects a year-on-year decline of 13.9% to 22.1% [1]. Group 2 - The company’s biological assets, mainly consisting of experimental monkeys, have seen a price increase due to rising market prices and natural growth, contributing positively to its performance [1][2]. - The price of experimental monkeys is closely linked to the innovation drug development climate, with prices having fluctuated significantly in recent years, peaking at over 200,000 yuan per monkey during the COVID-19 pandemic and dropping below 100,000 yuan in 2023 [2]. - As of 2025, the price of experimental monkeys is expected to rise again, surpassing 100,000 yuan each, driven by a recovery in the pharmaceutical capital market and increased licensing of domestic innovative drugs [2][3]. Group 3 - Zhaoyan New Drug's performance has experienced volatility in line with the fluctuations in experimental monkey prices, indicating a correlation between the demand for experimental monkeys and the recovery of the innovative drug development sector [3]. - Current market conditions show that the price of 3-5 year old experimental monkeys has risen to 140,000 yuan each, with a supply-demand imbalance indicating a recovery in the domestic innovative drug research and development environment [3].

证券日报网讯1月20日，昭衍新药（603127）在互动平台回答投资者提问时表示，公司具备OECD的 GLP认证资质，可以承接相关非临床服务项目，但来自欧盟地区的收入占比极低，不构成重要影响。 ...

Core Viewpoint - Zhaoyan New Drug (603127.SH) forecasts a net profit attributable to shareholders of approximately RMB 233 million to RMB 349 million for the year 2025, representing a year-on-year increase of about 214% to 371% [1] Group 1: Financial Performance - The increase in fair value is driven by a rise in market prices of biological assets and natural growth appreciation [1] - The laboratory operations have maintained a stable performance during the reporting period [1] Group 2: Revenue and Profitability - Due to the previous intense industry competition, the revenue and gross margin from performance contracts have decreased year-on-year [1] - The contribution of laboratory service business profits has declined [1]

Group 1 - Zhongshi Technology expects a net profit of 330 million to 370 million yuan for 2025, representing a year-on-year growth of 63.86% to 83.73% [1] - Yuegui Co. anticipates a net profit of 443 million to 503 million yuan for 2025, with a year-on-year increase of 59.03% to 80.57% [3] - Zhaoyan Pharmaceutical forecasts a net profit of 233 million to 349 million yuan for 2025, indicating a growth of 214% to 371% compared to the previous year [4] - Su Shi Testing predicts a net profit of 245 million to 265 million yuan for 2025, reflecting a year-on-year increase of 6.8% to 15.51% [5] - Zhongfu Industrial expects a net profit of 1.55 billion to 1.7 billion yuan for 2025, with an increase of 120.27% to 141.59% year-on-year [23] - Putailei anticipates a net profit of 2.3 billion to 2.4 billion yuan for 2025, representing a growth of 93.18% to 101.58% [16] - Qiaoyuan Co. expects a net profit of 226 million to 256 million yuan for 2025, indicating a year-on-year increase of 51.51% to 71.62% [17] - Hikvision forecasts a net profit of 14.188 billion yuan for 2025, with a year-on-year growth of 18.46% [18] - Huacheng Equipment predicts a net profit of 182 million to 212 million yuan for 2025, reflecting a growth of 193.64% to 242.04% [26] - Longhua Chemical expects a net profit of 89.41 million to 109 million yuan for 2025, with a year-on-year increase of 53.75% to 87.91% [27] - Xinyuan Biotech anticipates a net profit of 100 million to 130 million yuan for 2025, compared to a loss of 47.57 million yuan in the previous year [24] - Dongwei Technology forecasts a net profit of 120 million to 140 million yuan for 2025, indicating a growth of 73.23% to 102.10% [34] - Chip Microelectronics expects a net profit of 275 million to 295 million yuan for 2025, reflecting a year-on-year increase of 71.13% to 83.58% [41] Group 2 - Huangshan Tourism's subsidiary plans to invest approximately 133 million yuan in an upgrade project for the electric system of the Huangshan Taiping cableway, with a payback period of 4.38 years [2] - Nanjing Julong intends to invest 110 million yuan to establish a production line for modified plastics with an annual capacity of 60,000 tons [8] - Yongxing Materials has completed the commissioning of its lithium extraction project and achieved full production capacity [9] - Hengtong Co. plans to repurchase shares worth 80 million to 100 million yuan at a price not exceeding 14.5 yuan per share [12] - Fuxing Pharmaceutical's subsidiary received approval for clinical trials of a new drug for treating advanced colorectal cancer [13] - New Industry's syphilis antibody test kit has received IVDR CE certification [14] - Youxun Technology has established a wholly-owned subsidiary in Brazil with an investment of 10 million reais [15] - Guangdong Hongtu plans to invest up to 95 million yuan to establish a subsidiary in Thailand for automotive parts production [33]

证券代码：603127 证券简称：昭衍新药 公告编号：2026-003 北京昭衍新药研究中心股份有限公司 2025 年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 适用情形：实现盈利，且净利润与上年同期相比上升 50%以上 1. 预 计 2025 年 实 现 营 业 收 入 约 人 民 币 157,259.91 万 元 到 人 民 币 173,813.58 万元，与上年同期的数据相比，将减少约人民币 28,019.80 万元到 人民币 44,573.47 万元，同比减少约 13.9%到 22.1%。 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 公司财务部门初步测算如下： 1. 预 计 2025 年 实 现 营 业 收 入 约 人 民 币 157,259.91 万 元 到 人 民 币 173,813.58 万元，与上年同期的数据相比，将减少约人民币 28,019.80 万元到 人民币 44,573.47 万元，同比减少约 13.9%到 22.1%。 ...

格隆汇1月20日丨昭衍新药(603127.SH)公布，预计2025年实现营业收入约人民币15.73亿元到人民币 17.38亿元，与上年同期的数据相比，将减少约人民币28,019.80 万元到人民币 44,573.47 万元，同比减少 约 13.9%到 22.1%。 预计2025年实现归属于上市公司股东的净利润约人民币2.33亿元到人民币3.49亿元，与上年同期的数据 相比，将增加约人民币15,853.52万元到人民币 27,484.06万元，同比增加约214.0%到371.0%。 预计 2025 年实现归属于上市公司股东的扣除非经常性损益的净利润约人民币 24,638.00 万元到人民币 36,956.99 万元，与上年同期的数据相比，将增加约人民币 22,280.66 万元到人民币 34,599.65 万元，同 比增加约945.2%到1,467.7%。 ...